THE DEAL, AT A GLANCE
From the announcementLeal Therapeutics
01Who is involvedBacked by SV Health Investors, OrbiMed, Newpath Partners, Chugai Venture FundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedLeal Therapeutics raised $30M Pre-Seed, announced 2026-08-17From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersLeal Therapeutics is financing advancement of neuro-metabolic therapies for CNS disorders, with the round directed toward LTX-001 in schizophrenia and LTX-002 in ALS.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Leal Therapeutics · Financing Record
Explore source-linked visual explanations for Leal Therapeutics. Unsupported claims are withheld while source review continues.
Record 10423 · Recorded date: 2026-08-17
Explore company records →